LMK-235 is a selective inhibitor of histone deacetylases HDAC4 and HDAC5, making it a valuable tool in epigenetic research. It is primarily used in studies related to cancer, where modulation of HDAC activity can influence gene expression, cell proliferation, and apoptosis. LMK-235 has demonstrated anti-tumor effects in preclinical models, particularly in leukemia and solid tumors, by promoting the re-expression of tumor suppressor genes silenced in cancer cells. In addition to oncology, LMK-235 is investigated for its potential in neurodegenerative diseases. By altering histone acetylation, it may enhance the expression of neuroprotective genes and improve cognitive function in models of conditions like Alzheimer’s disease and Huntington’s disease. It is also used in research on inflammatory diseases and metabolic disorders, where HDAC4 and HDAC5 play regulatory roles in immune response and insulin signaling. Due to its selectivity, LMK-235 allows researchers to study the specific roles of class IIa HDACs without broad off-target effects, supporting the development of more precise therapeutic strategies.